Abstract
Despite intensive effort, biomarker research for the detection of prodromal stage, diagnosis and progression of Parkinson’s disease (PD) falls short of expectations. This article reviews the attempts in the last 20 years to find a biomarker, addresses challenges along the biomarker search and suggests the steps that should be taken to overcome these challenges. Although several biomarkers are currently available, none of them is specific enough for diagnosis, prediction of future PD or disease progression. The main reason for the failure finding a strong biomarker seems to be drastic heterogeneity of PD, which exhibits itself in all domains; from the clinic to pathophysiology or genetics. The diversity in patient selection, assessment methods or outcomes in biomarker studies also limit the interpretation and generalizability of the data. In search of a reliable biomarker, consideration of novel approaches encompassing individual demographic, clinical, genetic, epigenetic and environmental differences, employment of strategies enabling marker combinations, designing multicenter studies with compatible assessment methods, integration of data from preclinical domains and utilization of novel technology-based assessments are necessary.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andreasen N, Vanmechelen E, Van de Voorde A et al (1998) Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer’s disease: a community based follow up study. J Neurol Neurosurg Psychiatry 64:298–305
Berg D, Postuma RB, Bloem B et al (2014) Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. Mov Disord 29:454–462. https://doi.org/10.1002/mds.25844
Berg D, Postuma RB, Adler CH et al (2015) MDS research criteria for prodromal Parkinson’s disease. Mov Disord 30:1600–1611. https://doi.org/10.1002/mds.26431
Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95. https://doi.org/10.1067/mcp.2001.113989
Braak H, Del Tredici K, Rüb U et al Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24:197–211
Chahine LM, Stern MB (2017) Parkinson’s disease biomarkers: where are we and where do we go next? Mov Disord Clin Pract 4:796–805. https://doi.org/10.1002/mdc3.12545
Chen-Plotkin AS, Zetterberg H (2018) Updating our definitions of Parkinson’s disease for a molecular age. J Parkinson’s Dis 8:S53–S57. https://doi.org/10.3233/JPD-181487
Davis MY, Johnson CO, Leverenz JB et al (2016) Association of GBA mutations and the E326K polymorphism with motor and cognitive progression in Parkinson disease. JAMA Neurol 73:1217–1224. https://doi.org/10.1001/jamaneurol.2016.2245
De Marzi R, Seppi K, Högl B et al (2016) Loss of dorsolateral nigral hyperintensity on 3.0 T susceptibility-weighted imaging in idiopathic rapid eye movement sleep behavior disorder. Ann Neurol 79:1026–1030. https://doi.org/10.1002/ana.24646
Doppler K, Volkmann J, Sommer C (2016) Skin biopsies in the differential diagnosis of parkinsonism: are we ready for simplified protocols? Brain 139:e5. https://doi.org/10.1093/brain/awv251
Espay AJ, Brundin P, Lang AE (2017) Precision medicine for disease modification in Parkinson disease. Nat Rev Neurol 13:119–126. https://doi.org/10.1038/nrneurol.2016.196
Fereshtehnejad S-M, Montplaisir JY, Pelletier A et al (2017) Validation of the MDS research criteria for prodromal Parkinson’s disease: longitudinal assessment in a REM sleep behavior disorder (RBD) cohort. Mov Disord 32:865–873. https://doi.org/10.1002/mds.26989
Frosini D, Cosottini M, Donatelli G et al (2017) Seven tesla MRI of the substantia nigra in patients with rapid eye movement sleep behavior disorder. Parkinsonism Relat Disord 43:105–109. https://doi.org/10.1016/j.parkreldis.2017.08.002
Fullard ME, Morley JF, Duda JE (2017) Olfactory dysfunction as an early biomarker in Parkinson’s disease. Neurosci Bull 33:515–525. https://doi.org/10.1007/s12264-017-0170-x
Funke C, Schneider SA, Berg D, Kell DB (2013) Genetics and iron in the systems biology of Parkinson’s disease and some related disorders. Neurochem Int 62:637–652. https://doi.org/10.1016/j.neuint.2012.11.015
García-Lorenzo D, Longo-Dos Santos C, Ewenczyk C et al (2013) The coeruleus/subcoeruleus complex in rapid eye movement sleep behaviour disorders in Parkinson’s disease. Brain 136:2120–2129. https://doi.org/10.1093/brain/awt152
Gardner RC, Burke JF, Nettiksimmons J et al (2015) Traumatic brain injury in later life increases risk for Parkinson disease. Ann Neurol 77:987–995. https://doi.org/10.1002/ana.24396
Gardner RC, Byers AL, Barnes DE et al (2018) Mild TBI and risk of Parkinson disease. Neurology 90:e1771–e1779. https://doi.org/10.1212/WNL.0000000000005522
Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 51:745–752
Goldman SM, Kamel F, Ross GW et al (2012) Head injury, alpha-synuclein Rep1, and Parkinson’s disease. Ann Neurol 71:40–48. https://doi.org/10.1002/ana.22499
Goldstein DS, Holmes C, Bentho O et al (2008) Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat Disord 14:600–607. https://doi.org/10.1016/j.parkreldis.2008.01.010
Goldstein DS, Holmes C, Sharabi Y (2012) Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson’s disease and other synucleinopathies. Brain 135:1900–1913. https://doi.org/10.1093/brain/aws055
Halbgebauer S, Öckl P, Wirth K et al (2016) Protein biomarkers in Parkinson’s disease: focus on cerebrospinal fluid markers and synaptic proteins. Mov Disord 31:848–860. https://doi.org/10.1002/mds.26635
Hansen C, Sanchez-Ferro A, Maetzler W (2018) How mobile health technology and electronic health records will change care of patients with Parkinson’s disease. J Parkinson’s Dis 8:S41–S45. https://doi.org/10.3233/JPD-181498
Hansson O, Zetterberg H, Buchhave P et al (2006) Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5:228–234. https://doi.org/10.1016/S1474-4422(06)70355-6
Hansson O, Hall S, Ohrfelt A et al (2014) Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease. Alzheimers Res Ther 6:25. https://doi.org/10.1186/alzrt255
Heinzel S, Lerche S, Maetzler W, Berg D (2017) Global, yet incomplete overview of cohort studies in Parkinson’s disease. J Parkinson’s Dis 7:423–432. https://doi.org/10.3233/JPD-171100
Hentati F, Trinh J, Thompson C et al (2014) LRRK2 parkinsonism in Tunisia and Norway: a comparative analysis of disease penetrance. Neurology 83:568–569. https://doi.org/10.1212/WNL.0000000000000675
Herbert MK, Aerts MB, Beenes M et al (2015) CSF neurofilament light chain but not FLT3 ligand discriminates parkinsonian disorders. Front Neurol 6:91. https://doi.org/10.3389/fneur.2015.00091
Hong Z, Shi M, Chung KA et al (2010) DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain 133:713–726. https://doi.org/10.1093/brain/awq008
Hopfner F, Künstner A, Müller SH et al (2017) Gut microbiota in Parkinson disease in a northern German cohort. Brain Res 1667:41–45. https://doi.org/10.1016/j.brainres.2017.04.019
Jennings D, Siderowf A, Stern M et al (2017) Conversion to Parkinson disease in the PARS hyposmic and dopamine transporter-deficit prodromal cohort. JAMA Neurol 74:933–940. https://doi.org/10.1001/jamaneurol.2017.0985
Khalil M, Teunissen CE, Otto M et al (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14:577–589. https://doi.org/10.1038/s41582-018-0058-z
Kim R, Kim H-J, Kim A et al (2018) Peripheral blood inflammatory markers in early Parkinson’s disease. J Clin Neurosci 58:30–33. https://doi.org/10.1016/j.jocn.2018.10.079
Knudsen K, Borghammer P (2018) Imaging the Autonomic nervous system in parkinson’s disease. Curr Neurol Neurosci Rep 18:79. https://doi.org/10.1007/s11910-018-0889-4
Knudsen K, Fedorova TD, Hansen AK et al (2018) In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case–control study. Lancet Neurol 17:618–628. https://doi.org/10.1016/S1474-4422(18)30162-5
Lewis SJG, Foltynie T, Blackwell AD et al (2005) Heterogeneity of Parkinson’s disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry 76:343–348. https://doi.org/10.1136/jnnp.2003.033530
LeWitt P, Schultz L, Auinger P et al (2011) CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson’s disease. Brain Res 1408:88–97. https://doi.org/10.1016/j.brainres.2011.06.057
Lewitt PA, Li J, Lu M et al (2013) 3-hydroxykynurenine and other Parkinson’s disease biomarkers discovered by metabolomic analysis. Mov Disord 28:1653–1660. https://doi.org/10.1002/mds.25555
Lin Y-S, Lee W-J, Wang S-J, Fuh J-L (2018) Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. Sci Rep 8:17368. https://doi.org/10.1038/s41598-018-35766-w
Mahlknecht P, Gasperi A, Willeit P et al (2016) Prodromal Parkinson’s disease as defined per MDS research criteria in the general elderly community. Mov Disord 31:1405–1408. https://doi.org/10.1002/mds.26674
Marek K, Jennings D, Lasch S et al (2011) The Parkinson progression marker initiative (PPMI). Prog Neurobiol 95:629–635. https://doi.org/10.1016/j.pneurobio.2011.09.005
Marras C, Lang A (2013) Parkinson’s disease subtypes: lost in translation? J Neurol Neurosurg Psychiatry 84:409–415. https://doi.org/10.1136/jnnp-2012-303455
Marras C, Rochon P, Lang AE (2002) Predicting motor decline and disability in Parkinson disease. Arch Neurol 59:1724. https://doi.org/10.1001/archneur.59.11.1724
Meles SK, Renken RJ, Janzen A et al (2018) The metabolic pattern of idiopathic REM sleep behavior disorder reflects early-stage parkinson disease. J Nucl Med 59:1437–1444. https://doi.org/10.2967/jnumed.117.202242
Mondello S, Constantinescu R, Zetterberg H et al (2014) CSF α-synuclein and UCH-L1 levels in Parkinson’s disease and atypical parkinsonian disorders. Parkinsonism Relat Disord 20:382–387. https://doi.org/10.1016/j.parkreldis.2014.01.011
Navarro-Sánchez L, Águeda-Gómez B, Aparicio S, Pérez-Tur J (2018) Epigenetic study in Parkinson’s disease: a pilot analysis of DNA methylation in candidate genes in brain. Cells 7:150. https://doi.org/10.3390/cells7100150
Nilsonne G, Lekander M (2017) Circulating interleukin 6 in Parkinson disease. JAMA Neurol 74:607–608. https://doi.org/10.1001/jamaneurol.2017.0037
Obeso JA, Stamelou M, Goetz CG et al (2017) Past, present, and future of Parkinson’s disease: a special essay on the 200th Anniversary of the Shaking Palsy. Mov Disord 32:1264–1310. https://doi.org/10.1002/mds.27115
Parkinson J (1817) An essay on the shaking palsy. Whittingham and Rowland Sherwood, Neely and Jones, London
Pilotto A, Heinzel S, Suenkel U et al (2017) Application of the movement disorder society prodromal Parkinson’s disease research criteria in 2 independent prospective cohorts. Mov Disord. https://doi.org/10.1002/mds.27035
Ping L, Duong DM, Yin L et al (2018) Global quantitative analysis of the human brain proteome in Alzheimer’s and Parkinson’s disease. Sci data 5:180036. https://doi.org/10.1038/sdata.2018.36
Postuma RB, Berg D (2016) Advances in markers of prodromal Parkinson disease. Nat Rev Neurol 12:622–634. https://doi.org/10.1038/nrneurol.2016.152
Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30:1591–1601. https://doi.org/10.1002/mds.26424
Postuma RB, Poewe W, Litvan I et al (2018) Validation of the MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 33:1601–1608. https://doi.org/10.1002/mds.27362
Pyatigorskaya N, Gaurav R, Arnaldi D et al (2017) Magnetic resonance imaging biomarkers to assess substantia nigra damage in idiopathic rapid eye movement sleep behavior disorder. Sleep. https://doi.org/10.1093/sleep/zsx149
Rahmani F, Saghazadeh A, Rahmani M et al (2019) Plasma levels of brain-derived neurotrophic factor in patients with Parkinson disease: a systematic review and meta-analysis. Brain Res 1704:127–136. https://doi.org/10.1016/j.brainres.2018.10.006
Rolinski M, Griffanti L, Piccini P et al (2016) Basal ganglia dysfunction in idiopathic REM sleep behaviour disorder parallels that in early Parkinson’s disease. Brain 139:2224–2234. https://doi.org/10.1093/brain/aww124
Saal K-A, Galter D, Roeber S et al (2017) Altered expression of growth associated protein-43 and Rho kinase in human patients with Parkinson’s disease. Brain Pathol 27:13–25. https://doi.org/10.1111/bpa.12346
Santiago JA, Bottero V, Potashkin JA (2018) Evaluation of RNA blood biomarkers in the Parkinson’s disease biomarkers program. Front Aging Neurosci 10:157. https://doi.org/10.3389/fnagi.2018.00157
Saunders-Pullman R, Mirelman A, Alcalay RN et al (2018) Progression in the LRRK2-asssociated Parkinson disease population. JAMA Neurol 75:312–319. https://doi.org/10.1001/jamaneurol.2017.4019
Scheperjans F, Derkinderen P, Borghammer P (2018) The gut and Parkinson’s disease: hype or hope? J Parkinson’s Dis 8:S31–S39. https://doi.org/10.3233/JPD-181477
Siderowf A, Xie SX, Hurtig H et al (2010) CSF amyloid 1–42 predicts cognitive decline in Parkinson disease. Neurology 75:1055–1061. https://doi.org/10.1212/WNL.0b013e3181f39a78
Smith AR, Smith RG, Burrage J et al (2019) A cross-brain regions study of ANK1 DNA methylation in different neurodegenerative diseases. Neurobiol Aging 74:70–76. https://doi.org/10.1016/j.neurobiolaging.2018.09.024
Strimbu K, Tavel JA (2010) What are biomarkers? Curr Opin HIV AIDS 5:463–466. https://doi.org/10.1097/COH.0b013e32833ed177
Su X, Chu Y, Kordower JH et al (2015) PGC-1α promoter methylation in Parkinson’s disease. PLoS One 10:e0134087. https://doi.org/10.1371/journal.pone.0134087
Tokuda T, Qureshi MM, Ardah MT et al (2010) Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75:1766–1772. https://doi.org/10.1212/WNL.0b013e3181fd613b
Trupp M, Jonsson P, Ohrfelt A et al (2014) Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson’s disease. J Parkinson’s Dis 4:549–560. https://doi.org/10.3233/JPD-140389
van Nuenen BFL, van Eimeren T, van der Vegt JPM et al (2009) Mapping preclinical compensation in Parkinson’s disease: an imaging genomics approach. Mov Disord 24:S703–S710. https://doi.org/10.1002/mds.22635
van Dijk KD, Persichetti E, Chiasserini D et al (2013) Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson’s disease. Mov Disord 28:747–754. https://doi.org/10.1002/mds.25495
Vazquez Roque M, Bouras EP (2015) Epidemiology and management of chronic constipation in elderly patients. Clin Interv Aging 10:919–930. https://doi.org/10.2147/CIA.S54304
Vilas D, Iranzo A, Tolosa E et al (2016) Assessment of α-synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case–control study. Lancet Neurol 15:708–718. https://doi.org/10.1016/S1474-4422(16)00080-6
Visanji NP, Mollenhauer B, Beach TG et al (2017) The systemic synuclein sampling study: toward a biomarker for Parkinson’s disease. Biomark Med 11:359–368. https://doi.org/10.2217/bmm-2016-0366
Vos M, Esposito G, Edirisinghe JN et al (2012) Vitamin K2 is a mitochondrial electron carrier that rescues Pink1 deficiency. Science 336:1306–1310. https://doi.org/10.1126/science.1218632
Williams-Gray CH, Wijeyekoon R, Yarnall AJ et al (2016) Serum immune markers and disease progression in an incident Parkinson’s disease cohort (ICICLE-PD). Mov Disord 31:995–1003. https://doi.org/10.1002/mds.26563
Willkommen D, Lucio M, Moritz F et al (2018) Metabolomic investigations in cerebrospinal fluid of Parkinson’s disease. PLoS One 13:e0208752. https://doi.org/10.1371/journal.pone.0208752
Wüllner U, Kaut O, deBoni L et al (2016) DNA methylation in Parkinson’s disease. J Neurochem 139:108–120. https://doi.org/10.1111/jnc.13646
Zetterberg H, Schott JM (2019) Biomarkers for Alzheimer’s disease beyond amyloid and tau. Nat Med 25:201–203. https://doi.org/10.1038/s41591-019-0348-z
Zhu Z-G, Sun M-X, Zhang W-L et al (2017) The efficacy and safety of coenzyme Q10 in Parkinson’s disease: a meta-analysis of randomized controlled trials. Neurol Sci 38:215–224. https://doi.org/10.1007/s10072-016-2757-9
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Yilmaz, R., Hopfner, F., van Eimeren, T. et al. Biomarkers of Parkinson’s disease: 20 years later. J Neural Transm 126, 803–813 (2019). https://doi.org/10.1007/s00702-019-02001-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-019-02001-3